Material weakness
high
Filing comparison
Neuphoria Therapeutics Inc. reported a material weakness in internal control
Internal control reported effective → Material weakness in internal control
In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control — Integrated Framework (2013). Based on our assessments and those criteria, management determined that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weakness in our internal control over financial reporting, described above, as of June 30, 2026. This Annual Report on Form 10-K does…
Evidence
- Current state
- material_weakness
- Current state label
- Material weakness in internal control
- Direction
- newly reported
- Prior filed
- 2025-09-29
- Prior form
- 10-K
- Prior state
- effective
- Prior state label
- Internal control reported effective
- Remediation stated
- Yes
- Severity
- high
- Source
- Item 9A internal control conclusion, compared with the prior filing
- Why
- The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.